Protective Effect of Statin Use in the Progression of Dry to Exudative Age-Related Macular Degeneration

dc.contributor.advisorHaley, Roberten
dc.creatorNettune, Gregoryen
dc.date.accessioned2010-07-12T16:19:02Zen
dc.date.accessioned2014-02-19T22:00:31Z
dc.date.available2010-07-12T16:19:02Zen
dc.date.available2014-02-19T22:00:31Z
dc.date.issued2006-10-13en
dc.description.abstractPurpose: Age-related macular degeneration (ARMD) is a leading cause of irreversible blindness in the industrialized world. Studies suggest that HMG CoA reductase inhibitors (statins) might slow the progression of dry ARMD to the exudative stage. We set out to determine if statin use reduces the risk of progression to exudative ARMD in a matched case-control study. Methods: An epidemiological study of 61 cases with exudative ARMD matched by age, gender, and race to 61 controls with early, high-risk ARMD determined by prospective ophthalmologic examination. Results: The risk of exudative ARMD was increased by smoking within the past 20 years (OR=5.8, 95% CI 1.42-23.77) and reduced by use of statins (OR=0.2, 95% CI 0.04-0.93). Further, the duration of statin use up to four years was associated with an increasing degree of protection (9% reduction each month, 95% CI 0.85-0.98). Conclusion: Statin use may reduce the progression from dry to exudative ARMD.en
dc.format.digitalOriginborn digitalen
dc.format.mediumElectronicen
dc.format.mimetypeapplication/pdfen
dc.identifier.otheren
dc.identifier.urihttp://hdl.handle.net/2152.5/214en
dc.language.isoenen
dc.subjectMacular Degenerationen
dc.subjectBlindnessen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitorsen
dc.titleProtective Effect of Statin Use in the Progression of Dry to Exudative Age-Related Macular Degenerationen
dc.type.genredissertationen
dc.type.materialTexten
thesis.date.available2007-10-13en
thesis.degree.departmenten
thesis.degree.disciplineen
thesis.degree.grantorSouthwestern Medical Schoolen
thesis.degree.levelM.D.en
thesis.degree.nameMD with Distinction in Researchen

Files